TRULI

TRULI (CAS No.: 1424635-83-5) is a synthetic, ATP-competitive small-molecule LATS1/LATS2 kinase inhibitor, classified as a Hippo pathway modulator and chemical biology probe, specifically intended for mechanistic analysis and target validation in biomedical research and the early stages of drug discovery; by inhibiting LATS-mediated YAP phosphorylation, it promotes YAP/TAZ enrichment in the nucleus and enhances TEAD-driven gene expression, thereby providing a controllable intervention point for functional studies of regenerative signal transduction, mechanotransduction, and the Hippo network; in in vitro enzymatic evaluations, it typically exhibits nanomolar-level inhibitory activity, while in cellular models, commonly observed YAP dephosphorylation and transcriptional responses generally occur in the submicromolar to low micromolar range, with response magnitude and thresholds influenced by cell lineage, culture conditions, and assay endpoints; typical applications include inducing YAP nuclear localization in HEK293A cells and fibroblasts under starvation conditions, activating proliferative programs in models related to inner ear sensory epithelium and Müller glial cells, and analyzing Hippo dependency in cardiomyocytes and hematopoietic system-derived cell lines, thereby supporting drug discovery scenarios such as pathway mapping, target validation, and phenotypic or target-based screening; the concentration and exposure time used in experiments should be optimized according to the specific experimental design, model properties, and established pharmacodynamic endpoints; this product is for laboratory research use only, suitable for in vitro and preclinical in vivo research, and is not for human or veterinary use.